Type 1 diabetes and interferon therapy: a nationwide survey in Japan.

ABSTRACT:

Objective

Interferon therapy can trigger induction of several autoimmune diseases, including type 1 diabetes. To assess the clinical, immunologic, and genetic characteristics of type 1 diabetes induced by interferon therapy, we conducted a nationwide cross-sectional survey.

Research design and methods

Clinical characteristics, anti-islet autoantibodies, and HLA-DR typing were examined in 91 patients for whom type 1 diabetes developed during or shortly after interferon therapy.

Results

Median age at the onset of type 1 diabetes was 56 (interquartile range 48-63) years and mean ± SD BMI was 20.8 ± 2.7 kg/m(2). The time period from the initiation of interferon therapy to type 1 diabetes onset in patients receiving pegylated interferon and ribavirin was significantly shor

SUBMITTER: Nakamura K 

PROVIDER: S-EPMC3161293 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature